Bausch + Lomb has announced the launch of PreserVision AREDS3 eye vitamins, a new formulation that combines the clinically proven AREDS2 nutrients recommended by the National Eye Institute with a proprietary B-vitamin complex intended to support macular health across a broader range of patients with age-related macular degeneration (AMD).

The product includes thiamin, riboflavin, niacin, pantothenic acid, vitamin B6, biotin, folate, and vitamin B12. Bausch + Lomb said the supplement is intended to provide support through antioxidant protection, cellular nutritional support, and improved nutrient absorption.

Recent research has examined potential associations between B-vitamin supplementation and AMD risk. A narrative review published in Ophthalmology and Therapy summarized findings from more than 20 human studies involving nearly 30,000 individuals. Among the cited studies was the Women’s Antioxidant and Folic Acid Cardiovascular Study, which reported an association between certain B-vitamin supplementation regimens and reduced AMD risk.

In a press release, Bausch + Lomb said that it is planning a long-term clinical trial to evaluate the PreserVision AREDS3 supplement.